Moreover, targeting B7-H3 with CAR-T cells has the potential to activate immune cells within the microenvironment of metastatic tumors by promoting tumor cells to express immune-activating cytokines or other regulatory factors, as suggested by our findings. This evidence concerns the gene CD276 and neoplasm.